271 related articles for article (PubMed ID: 21490132)
1. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Liu Y; Liu A; Li H; Li C; Lin J
Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
[TBL] [Abstract][Full Text] [Related]
2. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
[TBL] [Abstract][Full Text] [Related]
3. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells.
Liu Y; Liu A; Xu Z; Yu W; Wang H; Li C; Lin J
Apoptosis; 2011 May; 16(5):502-10. PubMed ID: 21311975
[TBL] [Abstract][Full Text] [Related]
4. Anticancer effects of celecoxib through inhibiton of STAT3 phosphorylation and AKT phosphorylation in nasopharyngeal carcinoma cell lines.
Liu DB; Long GX; Mei Q; Wang JF; Hu GY; Gan L; Li WW; Sun W; Liu SF; Jiang JZ; Hu GQ
Pharmazie; 2014 May; 69(5):358-61. PubMed ID: 24855827
[TBL] [Abstract][Full Text] [Related]
5. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
6. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.
Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J
Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994
[TBL] [Abstract][Full Text] [Related]
7. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
[TBL] [Abstract][Full Text] [Related]
8. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.
Lee S; Lee M; Kim JB; Jo A; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
Biochem Biophys Res Commun; 2016 May; 473(4):1247-1254. PubMed ID: 27091428
[TBL] [Abstract][Full Text] [Related]
9. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells.
Reed S; Li H; Li C; Lin J
Biochem Biophys Res Commun; 2011 Apr; 407(3):450-5. PubMed ID: 21397587
[TBL] [Abstract][Full Text] [Related]
11. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells.
Liu Y; Fuchs J; Li C; Lin J
Cell Cycle; 2010 Sep; 9(17):3423-7. PubMed ID: 20818158
[TBL] [Abstract][Full Text] [Related]
12. Norcantharidin inhibits IL-6-induced epithelial‑mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells.
Gao Y; Li W; Liu R; Guo Q; Li J; Bao Y; Zheng H; Jiang S; Hua B
Oncol Rep; 2017 Aug; 38(2):1224-1232. PubMed ID: 28677802
[TBL] [Abstract][Full Text] [Related]
13. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
14. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation.
Kang JH; Li MJ; Luan PP; Jiang DK; Chen YW; Xu X; Yu Q; Xu YW; Su Q; Peng WH; Jian WX
Cell Biol Int; 2020 Oct; 44(10):2053-2064. PubMed ID: 32584509
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
[TBL] [Abstract][Full Text] [Related]
16. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma.
Moran DM; Mayes N; Koniaris LG; Cahill PA; McKillop IH
Liver Int; 2005 Apr; 25(2):445-57. PubMed ID: 15780071
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.
Liu DB; Hu GY; Long GX; Qiu H; Mei Q; Hu GQ
Acta Pharmacol Sin; 2012 May; 33(5):682-90. PubMed ID: 22504904
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells.
Liu Y; Li PK; Li C; Lin J
J Biol Chem; 2010 Aug; 285(35):27429-27439. PubMed ID: 20562100
[TBL] [Abstract][Full Text] [Related]
20. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]